A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study Evaluating The Efficacy And Safety Of Tanezumab For The Treatment Of Moderate To Severe Pain Associated With Interstitial Cystitis/ Painful Bladder Syndrome (IC/PBS).

Trial Profile

A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study Evaluating The Efficacy And Safety Of Tanezumab For The Treatment Of Moderate To Severe Pain Associated With Interstitial Cystitis/ Painful Bladder Syndrome (IC/PBS).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Tanezumab (Primary)
  • Indications Interstitial cystitis; Pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 May 2015 Pooled analysis (1035, 1010, 1019) results presented at the 110th Annual Meeting of the American Urological Association.
    • 21 Mar 2012 This trial is recruiting in Belgium, Spain and suspended in Finland.
    • 20 Jan 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top